search
Back to results

Increasing Adherence to Lung Cancer Screening

Primary Purpose

Lung Cancer, Adherence, Patient

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Patient Nudge
Clinician Nudge
Sponsored by
Abramson Cancer Center at Penn Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Lung Cancer focused on measuring Screening, Nudge, Adherence, Implementation science, Behavioral science, Digital health

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinicians will be eligible if they: are practicing primary care or specialty care physicians at a recruiting site within the University of Pennsylvania Health System; care for patients who completed LCS via LDCT in 2019-2022; and do not opt-out of study participation. Patients will be eligible if they: are eligible for LCS based on 2021 US Preventive Services Task Force (USPSTF) population guidelines (aged 50-80; smoking history of 20-pack years; smoked within the last 15 years) completed LCS via LDCT in 2019-2022; have not been diagnosed with lung cancer; meet criteria for non-adherence; remain eligible for LCS during the trial enrollment period; and receive LCS care from a clinician that has not opted-out of study participation Exclusion Criteria: Patients will be excluded if they: a) have a highly suspicious baseline LDCT (Lung-RADS 4B/X) given the presence of existing clinical pathways to ensure adherence in this group

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    No Intervention

    Experimental

    No Intervention

    Arm Label

    Clinician Nudge

    No Clinician Nudge

    Patient Nudge

    No Patient Nudge

    Arm Description

    A pended order will prompt clinicians in this arm when a patient is due for lung cancer screening or diagnostic follow-up.

    Clinicians in this arm will not be prompted by a pended order when a patient is due for lung cancer screening or diagnostic follow-up.

    Patients in this arm will receive messaging designed to increase awareness of the benefits of LCS and remind patients that they are due for screening or recommended follow-up care.

    Patients in this arm will receive usual care.

    Outcomes

    Primary Outcome Measures

    Number of completed annual LCS in patients with a negative baseline screen (Lung Imaging Reporting and Data System (Lung-RADS) 1 or 2).
    Number of completed low-dose computed tomography (LDCT) scans among adults who are due for annual screening based on evidence-based guidelines.
    Number of completed recommended diagnostic follow-up scans or procedures in patients with a positive baseline screen (Lung-RADS 3 or 4a).
    Completion of recommended diagnostic follow-up scans or procedures among adults with positive baseline LDCT scan.

    Secondary Outcome Measures

    Reach
    Reach defined by proportion of patients who receive patient nudges and by the proportion of patients whose clinician acts upon clinician nudge (i.e., signs pended orders)

    Full Information

    First Posted
    March 23, 2023
    Last Updated
    September 15, 2023
    Sponsor
    Abramson Cancer Center at Penn Medicine
    Collaborators
    National Comprehensive Cancer Network, AstraZeneca
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05832008
    Brief Title
    Increasing Adherence to Lung Cancer Screening
    Official Title
    Increasing Equitable Adherence to Annual Lung Cancer Screening and Diagnostic Follow-up
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 30, 2023 (Anticipated)
    Primary Completion Date
    November 10, 2024 (Anticipated)
    Study Completion Date
    November 10, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Abramson Cancer Center at Penn Medicine
    Collaborators
    National Comprehensive Cancer Network, AstraZeneca

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Investigators are conducting a pragmatic randomized trial testing the effectiveness of patient and clinician nudge strategies on adherence to lung cancer screening (LCS) & diagnostic follow-up across eligible primary care clinicians & patients. Following the trial, a subsample of patients & clinicians will be invited to one-time semi-structured interview & survey to identify individual & system-level factors that may restrict or enhance the impact of strategies.
    Detailed Description
    Investigators will conduct a pragmatic clinical trial with a 2 x 2 factorial design with clinicians that provide care to screening-eligible patients who are overdue for annual screening or diagnostic evaluation. The specific nudge strategies to be tested are: 1) gain-framed messaging delivered via text messaging to prompt patient adherence to LCS guidelines (patient nudges); and 2) electronic health record (EHR) prompts alerting clinicians when their patients are due for annual screening or diagnostic follow-up (clinician nudges). The rationale for this study is that changing external stimuli to encourage adherence to evidence-based LCS guidelines will increase early detection of lung cancer by removing individual and system-level barriers to identifying and prompting patients who are due for care. The central hypothesis is that the combination of patient and clinician strategies will have the greatest effect on increasing adherence because it will target multilevel determinants of lung cancer screening identified in our prior research including limited screening knowledge and suboptimal EHR design. The proposed strategies are designed to support equitable implementation across diverse settings and populations.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lung Cancer, Adherence, Patient
    Keywords
    Screening, Nudge, Adherence, Implementation science, Behavioral science, Digital health

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Factorial Assignment
    Model Description
    At the start of the trial, clinicians who do not opt-out will be randomized to the intervention (clinician nudge) or control arm (no clinician nudge). Eligible patients will be randomized, stratified by clinician, to either the intervention (patient nudge) or control group (no patient nudge).
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    1400 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Clinician Nudge
    Arm Type
    Experimental
    Arm Description
    A pended order will prompt clinicians in this arm when a patient is due for lung cancer screening or diagnostic follow-up.
    Arm Title
    No Clinician Nudge
    Arm Type
    No Intervention
    Arm Description
    Clinicians in this arm will not be prompted by a pended order when a patient is due for lung cancer screening or diagnostic follow-up.
    Arm Title
    Patient Nudge
    Arm Type
    Experimental
    Arm Description
    Patients in this arm will receive messaging designed to increase awareness of the benefits of LCS and remind patients that they are due for screening or recommended follow-up care.
    Arm Title
    No Patient Nudge
    Arm Type
    No Intervention
    Arm Description
    Patients in this arm will receive usual care.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Patient Nudge
    Intervention Description
    Framed Messaging - brief persuasive messaging to increase awareness about the risks and benefits of lung cancer screening and completion of recommended follow-up sent to patients via text message.
    Intervention Type
    Behavioral
    Intervention Name(s)
    Clinician Nudge
    Intervention Description
    EHR-based Prompts - an EHR-based prompt that alerts a clinician if a patient is due for screening or diagnostic follow-up.
    Primary Outcome Measure Information:
    Title
    Number of completed annual LCS in patients with a negative baseline screen (Lung Imaging Reporting and Data System (Lung-RADS) 1 or 2).
    Description
    Number of completed low-dose computed tomography (LDCT) scans among adults who are due for annual screening based on evidence-based guidelines.
    Time Frame
    Initial measurement will occur 3 months after randomization
    Title
    Number of completed recommended diagnostic follow-up scans or procedures in patients with a positive baseline screen (Lung-RADS 3 or 4a).
    Description
    Completion of recommended diagnostic follow-up scans or procedures among adults with positive baseline LDCT scan.
    Time Frame
    Initial measurement will occur 3 months after randomization
    Secondary Outcome Measure Information:
    Title
    Reach
    Description
    Reach defined by proportion of patients who receive patient nudges and by the proportion of patients whose clinician acts upon clinician nudge (i.e., signs pended orders)
    Time Frame
    Initial measurement will occur 3 months after randomization
    Other Pre-specified Outcome Measures:
    Title
    Rate of false-positive screens
    Description
    Defined as having a positive LDCT and no subsequent lung cancer diagnosis within 6 months of the LDCT date
    Time Frame
    6 months after LDCT date
    Title
    Number of downstream imaging and diagnostic procedures
    Description
    Measured using EHR data
    Time Frame
    6 months after LDCT date
    Title
    Number of lung cancer diagnoses
    Description
    Biopsy confirmed lung cancer diagnosis measured using EHR data
    Time Frame
    6 months after LDCT date

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    50 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Clinicians will be eligible if they: are practicing primary care or specialty care physicians at a recruiting site within the University of Pennsylvania Health System; care for patients who completed LCS via LDCT in 2019-2022; and do not opt-out of study participation. Patients will be eligible if they: are eligible for LCS based on 2021 US Preventive Services Task Force (USPSTF) population guidelines (aged 50-80; smoking history of 20-pack years; smoked within the last 15 years) completed LCS via LDCT in 2019-2022; have not been diagnosed with lung cancer; meet criteria for non-adherence; remain eligible for LCS during the trial enrollment period; and receive LCS care from a clinician that has not opted-out of study participation Exclusion Criteria: Patients will be excluded if they: a) have a highly suspicious baseline LDCT (Lung-RADS 4B/X) given the presence of existing clinical pathways to ensure adherence in this group
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Katharine Rendle, PhD,MSW,MPH
    Phone
    215-349-5442
    Email
    katharine.rendle@pennmedicine.upenn.edu
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jocelyn Wainwright, MS
    Phone
    215-615-4226
    Email
    Jocelyn.Wainwright@pennmedicine.upenn.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Katharine Rendle, PhD,MSW,MPH
    Organizational Affiliation
    University of Pennsylvania
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Anil Vachani, MD
    Organizational Affiliation
    University of Pennsylvania
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Increasing Adherence to Lung Cancer Screening

    We'll reach out to this number within 24 hrs